BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35263119)

  • 1. TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
    Delahunty R; Nguyen L; Craig S; Creighton B; Ariyaratne D; Garsed DW; Christie E; Fereday S; Andrews L; Lewis A; Limb S; Pandey A; Hendley J; Traficante N; Carvajal N; Spurdle AB; Thompson B; Parsons MT; Beshay V; Volcheck M; Semple T; Lupat R; Doig K; Yu J; Chen XQ; Marsh A; Love C; Bilic S; Beilin M; Nichols CB; Greer C; Lee YC; Gerty S; Gill L; Newton E; Howard J; Williams R; Norris C; Stephens AN; Tutty E; Smyth C; O'Connell S; Jobling T; Stewart CJR; Tan A; Fox SB; Pachter N; Li J; Ellul J; Mir Arnau G; Young MA; Gordon L; Forrest L; Harris M; Livingstone K; Hill J; Chenevix-Trench G; Cohen PA; Webb PM; Friedlander M; James P; Bowtell D; Alsop K;
    J Clin Oncol; 2022 Jun; 40(18):2036-2047. PubMed ID: 35263119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
    Tone AA; McCuaig JM; Ricker N; Boghosian T; Romagnuolo T; Stickle N; Virtanen C; Zhang T; Kim RH; Ferguson SE; May T; Laframboise S; Armel S; Demsky R; Volenik A; Stuart-McEwan T; Shaw P; Oza A; Kamel-Reid S; Stockley T; Bernardini MQ
    Gynecol Oncol; 2021 Jul; 162(1):97-106. PubMed ID: 33858678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake of testing for germline
    Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
    Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach.
    Moss HA; Samimi G; Havrilesky LJ; Sherman ME; Myers ER
    Genet Epidemiol; 2018 Feb; 42(1):117-122. PubMed ID: 29193313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
    Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cascade testing in Italian Hereditary Breast Ovarian Cancer families: a missed opportunity for cancer prevention?
    Trevisan L; Godino L; Battistuzzi L; Innella G; Luppi E; Buzzatti G; Gismondi V; Blondeaux E; Bonelli LA; Turchetti D; Varesco L
    Fam Cancer; 2024 Jun; 23(2):197-207. PubMed ID: 37968543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
    Samimi G; Bernardini MQ; Brody LC; Caga-Anan CF; Campbell IG; Chenevix-Trench G; Couch FJ; Dean M; de Hullu JA; Domchek SM; Drapkin R; Spencer Feigelson H; Friedlander M; Gaudet MM; Harmsen MG; Hurley K; James PA; Kwon JS; Lacbawan F; Lheureux S; Mai PL; Mechanic LE; Minasian LM; Myers ER; Robson ME; Ramus SJ; Rezende LF; Shaw PA; Slavin TP; Swisher EM; Takenaka M; Bowtell DD; Sherman ME
    J Clin Oncol; 2017 Jul; 35(20):2329-2337. PubMed ID: 28398847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
    Katapodi MC; Northouse L; Pierce P; Milliron KJ; Liu G; Merajver SD
    Oncol Nurs Forum; 2011 Sep; 38(5):572-81. PubMed ID: 21875844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake.
    Weinmann S; Phillips S; Sweet K; Cosgrove CM; Senter L
    Gynecol Oncol; 2022 Mar; 164(3):615-621. PubMed ID: 34998598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
    Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
    Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
    McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ
    Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
    Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
    Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of hereditary BRCA1 gene mutations in women with familial breast or ovarian cancer and the frequency of occurrence of these tumours in their relatives.
    Skasko E; Paszko Z; Niwińska A; Kwiatkowska E; Kruczek A; Pieńkowski T
    Eur J Gynaecol Oncol; 2004; 25(4):470-4. PubMed ID: 15285306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From Probands to Relatives: Communication of Genetic Risk for Hereditary Breast-Ovarian Cancer and Its Influence on Subsequent Testing.
    Seven M; Shah LL; Yazici H; Daack-Hirsch S
    Cancer Nurs; 2022 Jan-Feb 01; 45(1):E91-E98. PubMed ID: 32804756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.